Shalini Shenoy

Medicine & Life Sciences

1. Cell Transplantation 100%
2. Sickle Cell Anemia 99%
3. Transplants 89%
4. Unrelated Donors 75%
5. Transplantation 71%
6. Tissue Donors 68%
7. Hematopoietic Stem Cell Transplantation 60%
8. Graft vs Host Disease 60%
9. Child 45%
10. Pediatrics 42%
11. Bone Marrow 39%
12. Stem Cell Transplantation 38%
13. Allogeneic Cells 36%
14. Alemtuzumab 34%
15. Peripheral Blood Stem Cells 32%
16. Fetal Blood 24%
17. Chimerism 23%
18. Thalassemia 22%
19. Hemoglobinopathies 21%
20. Immune Reconstitution 20%
21. fludarabine 20%
22. Stem Cells 19%
23. Siblings 19%
24. Peripheral Blood Stem Cell Transplantation 17%
25. Melphalan 17%
26. Graft Rejection 15%
27. Abatacept 15%
28. Survival 15%
29. Safety 15%
30. Chronic Granulomatous Disease 14%
31. T-Lymphocytes 14%
32. Therapeutics 13%
33. Granulocyte Colony-Stimulating Factor 13%
34. Homologous Transplantation 13%
35. B-Lymphocytes 13%
36. Rituximab 13%
37. Autoimmune Lymphoproliferative Syndrome 13%
38. Transplant Recipients 12%
39. Progression-Free Survival 11%
40. Dyskeratosis Congenita 11%
41. Hematologic Neoplasms 11%
42. Neutrophils 11%
43. Clinical Trials 11%
44. Acute Myeloid Leukemia 11%
45. Primary Immunodeficiency Diseases 11%
46. Granulocytes 10%
47. Mortality 10%
48. Immunosuppression 10%
49. Mucopolysaccharidosis I 10%
50. Hydroxychloroquine 9%